Frank P. Zemlan
Algemeen Directeur bij Phase 2 Discovery, Inc.
Actieve functies van Frank P. Zemlan
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Phase 2 Discovery, Inc.
 Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Algemeen Directeur | - | - |
Loopbaan van Frank P. Zemlan
Eerdere bekende functies van Frank P. Zemlan
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - | - |
| GSK PLC | Corporate Officer/Principal | - | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Opleiding van Frank P. Zemlan
| Villanova University | Graduate Degree |
| University of Pennsylvania | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Corporate Officer/Principal | 3 |
| Chief Executive Officer | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Health Technology |
| Aventis, Inc. |
- Beurs
- Insiders
- Frank P. Zemlan
- Ervaring
